The effect of ATRA treatment (1 μM) on ex vivo high grade serous ovarian cancer tissues was assessed by immunohistochemistry using antibodies to cleaved caspase 3 (Fig. 6a) and Ki67 (Fig. 6b), respectively. This evidence concerns the gene CASP3 and ovarian serous adenocarcinoma.